Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce

This article was originally published in The Pink Sheet Daily

Executive Summary

AMT halves head count and restructures following second rejection by European regulators of its potential gene therapy, Glybera.

You may also be interested in...



EU's CHMP Clears Europe's First Gene Therapy, UniQure's Glybera

After three previous negative votes, the Netherlands biotech uniQure gains the first positive opinion from the Committee for Medicinal Products for Human Use for a gene therapy in Europe. Glybera is used to treat the ultra-rare condition lipoprotein lipase deficiency.

Gene Therapy Firm AMT Forced To Go Private, Backed By Forbion

Amsterdam Molecular Therapeutics plans to be acquired by a newly formed private company, uniQure, and to delist from Euronext.

Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma

Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel